Hepatocellular carcinoma: current questions and future directions.
Stanford Hospital and Medical Center, Stanford, California.
Robert G
RG
Gish
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers; D001706:Biopsy / Q000009:adverse effects / Q000379:methods; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003952:Diagnostic Imaging / Q000379:methods; D055808:Drug Discovery; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D009536:Niacinamide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000494:pharmacology / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000077157:Sorafenib; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D015415:Biomarkers; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib